ArticleScientific reports2024
Hybrids of copper cysteamine nanosheets and silver nanocluster ensure superior bactericidal capability via enhanced photodynamic effect.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- BifunctionalGels (Basel, Switzerland) · 2026Article
- Engineered metallic hybrid nanozyme for advanced inflammatory disease therapy.Materials today. Bio · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
Over the past decades, bacterial infections resulting from the misuse of antibiotics have garnered significant attention. Among the alternative antibacterial strategies, photodynamic therapy (PDT) has emerged as a promising non-antibiotic approach. However, persistent bacterial biofilms, particularly those composed of gram-negative bacteria with their protective outer membranes, have exhibited remarkable resilience to PDT. To address this challenge, we have developed an antibacterial composite material, silver nanoparticles coated-copper cysteamine (Cu-Cy-PEG@AgNPs), which demonstrates remarkable antibacterial activity against both gram-positive and gram-negative bacteria. Specifically, under UV irradiation, Cu-Cy-PEG@AgNPs achieves a sterilization efficiency of approximately 100% at a low concentration of 25 µg/mL. The incorporation of silver nanoparticles significantly enhances the antibacterial performance of Cu-Cy, effectively eradicating persistent bacterial biofilm infections. Moreover, Cu-Cy-PEG@AgNPs exhibits excellent biocompatibility with L929 cells, indicating its potential for use in relevant applications to combat bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.